PROMETHEUS® Thiopurine Metabolites
Cat. # 3200

Test Description

PROMETHEUS® Thiopurine Metabolites testing assists physicians in optimizing ongoing dosing of thiopurine immunosuppressant therapy to reach and maintain therapeutic goal. Thiopurine metabolite testing also helps to identify drug metabolite levels that may lead to toxicity and some of the reasons for treatment failure.

- A quantitative evaluation of 6-TGN (thioguanine nucleotide) and 6-MMPN (methyl mercaptopurine nucleotide)
- **Specimen Requirements** - 5.0 mL Whole Blood in EDTA / Lavender Top Tube
- **Shipping Requirements** – Ambient or cold pack (Do Not Freeze)
- **Storage Stability** – 3 days ambient, 8 days refrigerated
- **Turn Around Time** – 3 business days from date of receipt

Test Information

<table>
<thead>
<tr>
<th>Catalog Number</th>
<th>Test Name</th>
<th>Assay</th>
<th>Reference Value</th>
<th>Result Identifier*</th>
</tr>
</thead>
<tbody>
<tr>
<td>3200</td>
<td>Thiopurine Metabolites</td>
<td>6-MMPN, Quantitative HPLC</td>
<td>&lt; 5700 pmole/8X10^8 RBC</td>
<td>A00009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-TGN, Quantitative HPLC</td>
<td>230 – 400 pmole/8X10^8 RBC</td>
<td>A00010</td>
</tr>
</tbody>
</table>

*Result identifier provided for use in HL7 applications.

Laboratory Description

- Prometheus is located in San Diego, CA. **Tax ID#** 33-0685754 **NPI#** 1073642641.
- Licensed in several states including New York and California.
- This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. Prometheus Laboratories Inc. is a CAP-accredited CLIA laboratory.

CPT Codes (as applied by Prometheus)

- **82491(X2)**, Quantitative HPLC (High Pressure Liquid Chromatography) for each nucleotide in peripheral RBC, separate stationary and mobile phase.

Literature References


- Seidman E.G., Clinical use and practical application of TPMT Enzyme and 6-mercaptopurine metabolite monitoring in IBD. *Rev Gastroenterol Disord*. 2003;3(suppl 1):S30-S38.


